TScan Therapeutics, Inc. (TCRX)Healthcare | Biotechnology | Waltham, United States | NasdaqGM
1.19 USD
+0.11
(10.185%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.19 Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:54 p.m. EDT
TCRX is a non-buy due to imminent near-term downside pressure from paused trial enrollment and a forecasting model predicting -8.3% returns, compounded by permanent long-term damage from a strategy pivot that signals a deteriorating core asset (solidum apoptosis) and failed clinical momentum. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.051861 |
| MSTL | 0.077731 |
| AutoTheta | 0.083594 |
| AutoETS | 0.083637 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 78% |
| H-stat | 0.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.399 |
| Excess Kurtosis | 0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 76.459 |
| Revenue per Share | 0.08 |
| Market Cap | 67,712,936 |
| Forward P/E | -1.55 |
| Beta | 1.02 |
| Website | https://www.tscan.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22222221 |
| Address1 | 830 Winter Street |
| All Time High | 14.71 |
| All Time Low | 0.882 |
| Ask | 1.2 |
| Ask Size | 12 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,703,250 |
| Average Daily Volume3 Month | 717,453 |
| Average Volume | 717,453 |
| Average Volume10Days | 1,703,250 |
| Beta | 1.015 |
| Bid | 1.17 |
| Bid Size | 12 |
| Book Value | 2.164 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.19 |
| Current Ratio | 8.409 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.2 |
| Day Low | 1.11 |
| Debt To Equity | 76.459 |
| Display Name | TScan Therapeutics |
| Earnings Timestamp End | 1,762,954,200 |
| Earnings Timestamp Start | 1,762,954,200 |
| Ebitda | -130,947,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.072 |
| Enterprise To Revenue | 0.915 |
| Enterprise Value | 9,444,931 |
| Eps Current Year | -0.7325 |
| Eps Forward | -0.7675 |
| Eps Trailing Twelve Months | -1.0 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.04814 |
| Fifty Day Average Change | 0.14186001 |
| Fifty Day Average Change Percent | 0.13534452 |
| Fifty Two Week Change Percent | -22.222221 |
| Fifty Two Week High | 2.57 |
| Fifty Two Week High Change | -1.3799999 |
| Fifty Two Week High Change Percent | -0.53696495 |
| Fifty Two Week Low | 0.882 |
| Fifty Two Week Low Change | 0.30800003 |
| Fifty Two Week Low Change Percent | 0.34920636 |
| Fifty Two Week Range | 0.882 - 2.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,442,200,000 |
| Float Shares | 47,787,121 |
| Forward Eps | -0.7675 |
| Forward P E | -1.5504887 |
| Free Cashflow | -97,246,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 142 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -102,225,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00228 |
| Held Percent Institutions | 0.65742 |
| Implied Shares Outstanding | 56,901,623 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. |
| Long Name | TScan Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 67,712,936 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_583057578 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -129,766,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 67,712,930 |
| Number Of Analyst Opinions | 4 |
| Open | 1.12 |
| Operating Cashflow | -135,319,008 |
| Operating Margins | -8.515 |
| Payout Ratio | 0.0 |
| Phone | 857 399 9500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.19 |
| Post Market Time | 1,776,470,138 |
| Previous Close | 1.08 |
| Price Eps Current Year | -1.6245735 |
| Price Hint | 4 |
| Price To Book | 0.5499076 |
| Price To Sales Trailing12 Months | 6.5581536 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.152 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 10.1852 |
| Regular Market Day High | 1.2 |
| Regular Market Day Low | 1.11 |
| Regular Market Day Range | 1.11 - 1.2 |
| Regular Market Open | 1.12 |
| Regular Market Previous Close | 1.08 |
| Regular Market Price | 1.19 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,249,752 |
| Return On Assets | -0.27882 |
| Return On Equity | -0.71282 |
| Revenue Growth | 2.86 |
| Revenue Per Share | 0.08 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 52,625,035 |
| Shares Percent Shares Out | 0.033099998 |
| Shares Short | 1,885,270 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,930,510 |
| Short Name | TScan Therapeutics, Inc. |
| Short Percent Of Float | 0.0403 |
| Short Ratio | 3.16 |
| Source Interval | 15 |
| State | MA |
| Symbol | TCRX |
| Target High Price | 7.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 152,406,000 |
| Total Cash Per Share | 2.678 |
| Total Debt | 94,138,000 |
| Total Revenue | 10,325,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.41233 |
| Two Hundred Day Average Change | -0.22232997 |
| Two Hundred Day Average Change Percent | -0.1574207 |
| Type Disp | Equity |
| Volume | 1,249,752 |
| Website | https://www.tscan.com |
| Zip | 2,451 |